{"prompt": "['GB001, Inc.', 'GB001', 'Protocol GB001-2101', 'Version 5.0, 16 Apr 2020', 'CLINICAL STUDY PROTOCOL', 'Protocol Title:', 'A Phase 2a, Randomized, Double-Blind, Placebo-Controlled, Multi-', 'Center Study to Evaluate the Effect of GB001 in Patients with Chronic', 'Rhinosinusitis with or without Nasal Polyps', 'Protocol Number:', 'GB001-2101', 'Compound Number:', 'GB001', 'Study Phase:', 'Phase 2a', 'Short Title:', 'GB001 in Adult Subjects with Chronic Rhinosinusitis', 'Sponsor Name:', 'GB001, Inc., a wholly owned subsidiary of Gossamer Bio, Inc.', 'Legal Registered', '3013 Science Park Road, Suite 200', 'Address:', 'San Diego, CA 92121, USA', 'Regulatory Agency', 'Identifier Number:', 'EudraCT:', '2019-001682-33', 'Version:', '5.0', 'Approval Date:', '16 April 2020', 'Confidential', 'This document contains proprietary and confidential information of GB001, Inc. Acceptance of', 'this document constitutes agreement by the recipient that no previously unpublished information', 'contained herein will be published or disclosed without the prior written approval of GB001,', 'Inc. The following exceptions may occur under the condition that the party has agreed to keep', 'this information confidential: 1) disclosure of information to the extent necessary to obtain', 'informed consent, 2) disclosure of the document to study personnel under your supervision who', 'need to know the contents for conducting the study, and 3) disclosure of the document to', 'appropriate Institutional Review Boards (IRBs)/Independent Ethics Committees (IEC). The', 'foregoing shall not apply to disclosure required by governmental regulations or laws; however,', 'GB001, Inc. shall be promptly notified of any such disclosure.', '1', 'CONFIDENTIAL']['GB001, Inc.', 'GB001', 'Protocol GB001-2101', 'Version 5.0, 16 Apr 2020', \"SPONSOR'S AUTHORIZED REPRESENTATIVE SIGNATURE PAGE\", 'Gossamer Bio Services, Inc. on behalf of GB001, Inc,', 'a wholly owned subsidiary of Gossamer Bio, Inc.', 'Medical Monitor name and contact information will be provided separately.', '2', 'CONFIDENTIAL']['GB001, Inc.', 'GB001', 'Protocol GB001-2101', 'Version 5.0, 16 Apr 2020', 'INVESTIGATOR AGREEMENT', 'GB001-2101: A Phase 2a, randomized, double-blind, placebo-controlled, multi-center study to', 'evaluate the effect of GB001 in patients with chronic rhinosinusitis with or without nasal polyps', 'I, the undersigned, have read this protocol and agree to conduct this protocol in accordance with', 'ethical principles as outlined in the International Council for Harmonisation of Technical', 'Requirements for Pharmaceuticals for Human Use (ICH) guidelines on Good Clinical Practice,', 'any applicable laws and requirements and any additional conditions mandated by a regulatory', 'authority and/or Institutional Review Board/Independent Ethics Committee (IRB/IEC).', 'I acknowledge that I am responsible for the overall study conduct and I agree to personally', 'conduct or supervise the described clinical study.', 'I', 'agree to ensure that the confidential information contained in this document will not be used for', 'any purpose other than the evaluation or conduct of the clinical investigation without the prior', 'written consent of GB001, Inc.', 'Signature', 'Name of Investigator', 'Date', '3', 'CONFIDENTIAL']\n\n###\n\n", "completion": "END"}